Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults
- DOI
- 10.1080/21645515.2024.2304974
- Published
- 2024-03-21
- Container
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/21645515.2024.2304974,
title = {Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults},
author = {Prasad S. Kulkarni and Chandrasekaran Padmapriyadarsini and Johan Vekemans and Ashish Bavdekar and Madhu Gupta and Praveen Kulkarni and B.S. Garg and Nithya J. Gogtay and Muralidhar Tambe and Sanjay Lalwani and Kiranjit Singh and Renuka Munshi and Sushant Meshram and T.S. Selvavinayagam and Krishna Pandey and Devi Madhavi Bhimarasetty and S.R. Ramakrishnan and Chetanraj Bhamare and Abhijeet Dharmadhikari and Chandrashekhar Budhawant and Cyrille J. Bonhomme and Madhuri Thakar and Swarali N. Kurle and Elizabeth J. Kelly and Manish Gautam and Nivedita Gupta and Samiran Panda and Balram Bhargava and Cyrus S. Poonawalla and Umesh Shaligram and Dhananjay Kapse and Bhagwat Gunale and Unknown and Anand Kawade and Arunkumar Gondhali and Mini P. Singh and Ritin Mohindra and Pratibha Pereiera and M R Narayana Murthy and Abhishek V. Raut and Chetna Maliye and Ashwini Kalantri and Vijaya L L Chaudhari and Charuta J Godbole and Malangori Parande and Nandakumar Salunke and Sonali Palkar and Neeta Hanumante and Piyush Chaudhari and Shilpa Karande and Dipti Kumbhar and Shilpa Gupta and Sajal Mitra and S Sudharshini and Prakash Venkatesan and Madhukar - and Abhik Sen and Sunita Sreegiri and Venkata Durga Prasad Vithanala and Tamilanbu Panneerselvam and Aiswarya M Nair and Atul Chaudhari and Silvester Patil},
year = {2024},
journal = {Human Vaccines \& Immunotherapeutics},
doi = {10.1080/21645515.2024.2304974},
url = {https://doi.org/10.1080/21645515.2024.2304974}
}RIS
TY - JOUR TI - Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults AU - Prasad S. Kulkarni AU - Chandrasekaran Padmapriyadarsini AU - Johan Vekemans AU - Ashish Bavdekar AU - Madhu Gupta AU - Praveen Kulkarni AU - B.S. Garg AU - Nithya J. Gogtay AU - Muralidhar Tambe AU - Sanjay Lalwani AU - Kiranjit Singh AU - Renuka Munshi AU - Sushant Meshram AU - T.S. Selvavinayagam AU - Krishna Pandey AU - Devi Madhavi Bhimarasetty AU - S.R. Ramakrishnan AU - Chetanraj Bhamare AU - Abhijeet Dharmadhikari AU - Chandrashekhar Budhawant AU - Cyrille J. Bonhomme AU - Madhuri Thakar AU - Swarali N. Kurle AU - Elizabeth J. Kelly AU - Manish Gautam AU - Nivedita Gupta AU - Samiran Panda AU - Balram Bhargava AU - Cyrus S. Poonawalla AU - Umesh Shaligram AU - Dhananjay Kapse AU - Bhagwat Gunale AU - Unknown AU - Anand Kawade AU - Arunkumar Gondhali AU - Mini P. Singh AU - Ritin Mohindra AU - Pratibha Pereiera AU - M R Narayana Murthy AU - Abhishek V. Raut AU - Chetna Maliye AU - Ashwini Kalantri AU - Vijaya L L Chaudhari AU - Charuta J Godbole AU - Malangori Parande AU - Nandakumar Salunke AU - Sonali Palkar AU - Neeta Hanumante AU - Piyush Chaudhari AU - Shilpa Karande AU - Dipti Kumbhar AU - Shilpa Gupta AU - Sajal Mitra AU - S Sudharshini AU - Prakash Venkatesan AU - Madhukar - AU - Abhik Sen AU - Sunita Sreegiri AU - Venkata Durga Prasad Vithanala AU - Tamilanbu Panneerselvam AU - Aiswarya M Nair AU - Atul Chaudhari AU - Silvester Patil PY - 2024 JO - Human Vaccines & Immunotherapeutics DO - 10.1080/21645515.2024.2304974 UR - https://doi.org/10.1080/21645515.2024.2304974 ER -
APA
Kulkarni, P. S., Padmapriyadarsini, C., Vekemans, J., Bavdekar, A., Gupta, M., Kulkarni, P., Garg, B., Gogtay, N. J., Tambe, M., Lalwani, S., Singh, K., Munshi, R., Meshram, S., Selvavinayagam, T., Pandey, K., Bhimarasetty, D. M., Ramakrishnan, S., Bhamare, C., Dharmadhikari, A., Budhawant, C., Bonhomme, C. J., Thakar, M., Kurle, S. N., Kelly, E. J., Gautam, M., Gupta, N., Panda, S., Bhargava, B., Poonawalla, C. S., Shaligram, U., Kapse, D., Gunale, B., Unknown, Kawade, A., Gondhali, A., Singh, M. P., Mohindra, R., Pereiera, P., Murthy, M. R. N., Raut, A. V., Maliye, C., Kalantri, A., Chaudhari, V. L. L., Godbole, C. J., Parande, M., Salunke, N., Palkar, S., Hanumante, N., Chaudhari, P., Karande, S., Kumbhar, D., Gupta, S., Mitra, S., Sudharshini, S., Venkatesan, P., -, M., Sen, A., Sreegiri, S., Vithanala, V. D. P., Panneerselvam, T., Nair, A. M., Chaudhari, A., & Patil, S. (2024). Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2024.2304974
Source records
- crossref · retrieved 2026-09-27T01:35:26.194Z